

# 1 Temporal multi-omic analysis of COVID-19 in end-stage kidney disease

2

3 Emily Stephenson<sup>1,2\*</sup>, Erin Macdonald-Dunlop<sup>3\*</sup>, Lisa M Dratva<sup>2,4,5\*</sup>, Rik G.H. Lindeboom<sup>2</sup>,  
4 Zewen Kelvin Tuong<sup>4,6</sup>, Win Min Tun<sup>1</sup>, Norzawani B Buang<sup>3</sup>, Stephane Ballereau<sup>2</sup>, Mia  
5 Cabantaus<sup>4,6</sup>, Ana Peñalver<sup>4,6</sup>, Elena Prigmore<sup>2</sup>, John R Ferdinand<sup>4,6</sup>, Benjamin J Stewart<sup>2,4,6</sup>,  
6 Jack Gisby<sup>3</sup>, Talat Malik<sup>3</sup>, Candice L Clarke<sup>3</sup>, Nicholas Medjeral-Thomas<sup>3</sup>, Maria Prendecki<sup>3</sup>,  
7 Stephen McAdoo<sup>3</sup>, Anais Portet<sup>4,6</sup>, Michelle Willicombe<sup>3,7</sup>, Eleanor Sandhu<sup>3,7</sup>, Matthew C.  
8 Pickering<sup>3</sup>, Marina Botto<sup>3</sup>, Sarah A. Teichmann<sup>2,5,4#</sup>, Muzlifah Haniffa<sup>2,1,8#</sup>, Menna R.  
9 Clatworthy<sup>4,6,2#</sup>, David C. Thomas<sup>3,4#</sup>, James E. Peters<sup>3#</sup>

## 10 Affiliations

11 <sup>1</sup> Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

12 <sup>2</sup> Cellular Genetics, Wellcome Sanger Institute, Hinxton, United Kingdom

13 <sup>3</sup> Department of Immunology and Inflammation, Imperial College London, London, United  
14 Kingdom

15 <sup>4</sup> Department of Medicine, University of Cambridge, Cambridge, United Kingdom

16 <sup>5</sup> Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge,  
17 United Kingdom,

18 <sup>6</sup> Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of  
19 Cambridge, Cambridge, United Kingdom

20 <sup>7</sup> Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust,  
21 Hammersmith Hospital, London, United Kingdom

22 <sup>8</sup> Department of Dermatology and NIHR Newcastle Biomedical Research Centre, Newcastle  
23 Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

24 \*Equal contribution

25 #Senior authors

26 Correspondence to [j.peters@imperial.ac.uk](mailto:j.peters@imperial.ac.uk)

## 27 Summary

28

29 Patients with end-stage kidney disease (ESKD) are at high risk of severe COVID-19. We  
30 performed longitudinal single cell multi-omic immune profiling of ESKD patients with COVID-  
31 19, sampled during two waves of the pandemic. Uniquely, for a subset of patients, we obtained  
32 samples before and during acute infection, allowing intra-individual comparison. Using single-  
33 cell transcriptome, surface proteome and immunoreceptor sequencing of 580,040 high-quality  
34 cells, derived from 187 longitudinal samples from 61 patients, we demonstrate widespread  
35 changes following infection. We identified gene expression signatures of severity, with the  
36 majority of pathways differentiating mild from severe disease in B cells and monocytes. For  
37 example, gene expression of *PLAC8*, a receptor known to modulate SARS-CoV-2 entry to  
38 cells, was a marker of severity in CD14+ monocytes. Longitudinal profiling demonstrated  
39 distinct temporal molecular trajectories in severe versus mild disease, including type 1 and  
40 type 2 interferon signalling, *MHC* gene expression and, in B cells, a proliferative signature  
41 (*KRAS* and *MYC*). Evaluation of clonal T cell dynamics showed that the fastest expanding  
42 clones were significantly enriched in known SARS-CoV-2 specific sequences and shared  
43 across multiple patients. Our analyses revealed novel TCR clones likely reactive to SARS-  
44 CoV-2. Finally, we identified a population of transcriptionally distinct monocytes that emerged  
45 in peripheral blood following glucocorticoid treatment. Overall, our data delineate the temporal

46 dynamics of the immune response in COVID-19 in a high-risk population and provide a  
47 valuable open-access resource.

48

## 49 **Introduction**

50

51 COVID-19, caused by the SARS-CoV-2 virus, displays marked clinical heterogeneity, varying  
52 from minimal symptoms to fatal disease. This variation in outcome is not random; severe or  
53 fatal COVID-19 disproportionately affects certain strata of the population. Demographic risk  
54 factors for severe COVID-19 include older age, male sex, and non-white ethnicity. Underlying  
55 medical conditions also impact the risk of severe COVID-19. End-stage kidney disease  
56 (ESKD) is one of the strongest risk factors for severe COVID-19, with a UK population-scale  
57 study estimating a hazard ratio for death of 3.69<sup>1</sup>. While vaccines have been highly effective  
58 in reducing morbidity and mortality from SARS-CoV-2, novel viral variants of concern (VoC)  
59 continue to emerge and ESKD patients remain at elevated risk of hospitalisation and death.  
60 There is, therefore, a need for research and therapeutic efforts focusing on ESKD patients  
61 and other high-risk groups.

62

63 A central feature of the pathophysiology of severe COVID-19 is an excessive host  
64 inflammatory response leading to tissue injury. Autopsies revealed an accumulation of  
65 activated immune cells but little or no active virus<sup>2</sup>. Severe disease is characterised by excess  
66 circulating monocytes, neutrophils and myeloid progenitors and elevated pro-inflammatory  
67 cytokines and chemokines, which contribute to endothelial damage and the formation of  
68 microthrombi. The importance of the host immune response is further underscored by the  
69 efficacy of therapies targeting inflammation. Glucocorticoids, which have pleiotropic effects on  
70 inflammatory pathways, and targeted inhibition of the IL6 signalling pathway, both reduce  
71 mortality in COVID-19<sup>3,4,5</sup>. Drugs targeting the JAK-STAT pathway also appear promising<sup>6</sup>.

72

73 ESKD is defined as irreversible loss of renal function with a glomerular filtration rate <15  
74 mls/min/1.73m<sup>2</sup> and is fatal without dialysis or transplantation. In addition to loss of glomerular  
75 filtration, ESKD is a systemic disease associated with profound changes in hormonal,  
76 cardiovascular and haematopoietic function<sup>7</sup>. Such disturbances of normal physiology are also  
77 associated with changes in immune function, and ESKD patients have both increased  
78 susceptibility to infection and impaired vaccination responses<sup>8</sup>. Conversely, despite evidence  
79 of impaired specific adaptive immune responses, ESKD is also characterised by a chronic pro-  
80 inflammatory state<sup>7</sup>.

81

82 Thus, patients with ESKD may be at high risk of complications of SARS-CoV-2 due to their  
83 preponderance of cardiometabolic risk factors, as well as both impaired immunity and pro-  
84 inflammatory state secondary to uraemia. An outstanding question is whether patients with  
85 ESKD mount a qualitatively different immune response to SARS-CoV-2 that drives their  
86 susceptibility to severe COVID-19. Furthermore, the need to attend medical facilities for  
87 regular haemodialysis, regardless of infection with SARS-CoV-2, provides a unique  
88 opportunity to evaluate the temporal dynamics of the host immune response through serial  
89 sample collection in both the inpatient and outpatient setting.

90

91 Here, we longitudinally profile the evolving immune cellular landscape driven by COVID-19  
92 infection in ESKD patients, allowing us to produce single-cell resolution multi-omic temporal  
93 trajectories in the context of renal failure. Uniquely, we collected samples from the same set

94 of individuals before and during SARS-CoV-2 infection. Our data provide a rich resource for  
95 examining the complex longitudinal dynamics of COVID-19 infection in the context of an  
96 important and clinically vulnerable patient group.

97

## 98 **Results**

99

### 100 **Longitudinal immune cell profiling in ESKD patients with COVID-19**

101

102 To investigate the dynamics of the immune cellular landscape in ESKD patients with COVID-  
103 19, we performed longitudinal blood sampling and profiling of peripheral blood mononuclear  
104 cells (PBMC) in ESKD patients. Patients were recruited from a single centre in London, UK,  
105 during two distinct waves of COVID-19. The first cohort ('2020 Cohort') (n=22) were recruited  
106 in April-May 2020, during the initial phase of the pandemic and before the advent of  
107 vaccination. This cohort consisted of COVID-19 positive ESKD patients, including both  
108 inpatients and outpatients, with a spectrum of illness severity from mild to critical (**Fig. 1A,**  
109 **Supp. Table 1**). Following COVID-19 diagnosis, serial blood sampling was performed over  
110 the course of the illness (**Fig 1B**). In addition, we recruited COVID-19 negative ESKD patients  
111 to provide an appropriate control group. This group was well-matched in terms of age, sex,  
112 and ethnicity (**Supp. Table 1**).

113

114 The second cohort ('2021 Cohort') (n=16) consisted of ESKD patients with COVID-19,  
115 sampled between January-March 2021 (when the alpha variant was the predominant variant  
116 in the UK). These patients were recruited as part of the COVID-19 negative control group in  
117 the 2020 Cohort. Again, serial blood sampling was performed during the acute illness. Thus,  
118 for the 2021 Cohort we had matched samples from pre-infection and during acute COVID-19,  
119 enabling intra-individual analysis. In addition, for a subset of the 2021 Cohort we collected a  
120 convalescent sample approximately 2 months after infection (n=10). (**Fig. 1A-B**).

121

122 To provide a comprehensive yet granular assessment of cellular and molecular changes, we  
123 used a single-cell multi-omic approach, performing Cellular Indexing of Transcriptomes and  
124 Epitopes by sequencing (CITE-seq) of PBMC samples with matched T cell receptor  
125 sequencing (TCR-seq) and B cell receptor sequencing (BCR-seq) (**Fig. 1A, Supp. Table 2**).  
126 To exclude low quality cells, we removed those with less than 200 genes, more than 10%  
127 mitochondrial reads and fewer than 1000 UMIs. We performed genotype-based  
128 demultiplexing of pooled samples (Methods) and removed cells with genotypes not fully  
129 resolvable. The full dataset consisted of 580,040 cells, representing 187 longitudinal samples  
130 from 61 patients (median of 3 samples per patient).

131

132 For initial cell type annotation, we separated the data analyses into three broad categories of  
133 cell types: i) B cells, ii) T cells and innate lymphocytes, and iii) myeloid and non-immune  
134 hematopoietic cells (**Fig. 1C**). Data were integrated per patient to account for technical  
135 artefacts (Methods). Using semi-automatic cell type annotations with CellTypist<sup>9</sup>, previously  
136 published COVID-19 reference atlases<sup>10,11</sup>, and canonical marker genes, we were able to  
137 identify 39 cell types (**Fig. 1C, Supp. Fig. 1A-D**). These comprised known subtypes of  
138 monocytes (classical CD14+ mono, non-classical CD16+ mono and intermediate CD14+  
139 CD16+ mono) and dendritic cells (DCs), plus sub-populations displaying an interferon-  
140 stimulated signature<sup>11</sup> and complement expressing CD16+ monocytes that we have described  
141 previously (**Fig. 1C, Supp. Fig. 1B**)<sup>10</sup>. Within the B cell compartment, we leveraged the

142 availability of paired single-cell BCR-seq and CITE-seq data to detect 9 sub-populations. (**Fig.**  
143 **1C, Supp. Fig. 1C**). Similarly, using TCR-seq and CITE-seq data, we were able to recover 15  
144 clusters encompassing T cells, natural killer (NK) cells and innate-like lymphocytes (ILC) (**Fig.**  
145 **1C, Supp. Fig. 1D**).

146

### 147 **Altered cellular and transcriptomic profiles in ESKD patients with COVID-19**

148

149 To understand the changes in peripheral immune cellular proportions in COVID-19, we  
150 compared samples from COVID-19 positive ESKD patients to those from COVID-19 negative  
151 ESKD patients. We first compared samples during the first week of COVID-19 (week 1) to  
152 COVID-19 negative samples. Analysis using broad cell type annotations showed a significant  
153 decrease in the relative abundance of the total monocyte population in COVID-19 positive  
154 versus COVID-19 negative ESKD patients (**Fig. 2A, Supp. Table 3**). More granular cell-type  
155 categorisation revealed that samples taken during week 1 from COVID-19 positive patients  
156 had a significantly lower relative abundance of all monocyte subsets including classical (CD14  
157 mono), non-classical (CD16 mono) and intermediate CD14+CD16+ (Int. mono) monocytes  
158 (**Fig. 2B-D, Supp. Table 3**). Relative abundances of CD8+ memory T cells and CD4+ CTL  
159 and DC3 were reduced while those of naive B cells increased (**Fig. 2E-H, Supp. Table 3**).  
160 There were no significant changes in cell abundance between samples taken in the second  
161 week of COVID-19 compared to the first week.

162

163 Next, to assess immune cell transcriptomic changes in COVID-19 in ESKD patients, we  
164 performed differential gene expression analysis within each cell type, comparing samples from  
165 COVID-19 positive and COVID-19 negative patients (**Supp. Table 4**). To identify the biological  
166 pathways implicated by these differentially expressed genes, we performed gene set  
167 enrichment analysis (**Supp. Table 5**). We observed widespread transcriptomic changes  
168 between COVID-19 positive and negative samples across numerous cell types. In the 2020  
169 Cohort, the most consistent finding was an enrichment of interferon alpha and beta response  
170 pathways across a broad range of innate and adaptive immune cells (**Fig. 2I, Supp. Table 5**).

171

172 B cells exhibited the greatest number of significantly enriched pathway terms, totalling 240  
173 pathways (**Supp. Table 5**). Many of these contain genes that are involved in the cell cycle and  
174 DNA repair, likely reflecting the strong B cell proliferative response involved in initiating  
175 adaptive immunity to SARS-CoV-2. Similarly, expression of genes relating to protein  
176 translation and post-translational modification were up-regulated, likely relating to the  
177 generation of an antibody response. Many of the enriched pathways were also noted in B cell  
178 antibody-secreting cells (B-ASC). Examining other cell types, we identified 19 enriched  
179 pathways in monocytes, 17 in NK cells, 15 in dendritic cells, 8 in CD4+ T cells, 7 in CD8+ T  
180 cells (**Fig. 2I, Supp. Table 5**).

181

182 Some pathways were significantly enriched between COVID-19 positive and COVID-19-  
183 negative ESKD samples across multiple cell types. For example, we observed a significant  
184 negative enrichment of the "Orexin Receptor Pathway" across multiple innate immune cell  
185 types, including monocytes (adjusted P  $2.36 \times 10^{-5}$ ), dendritic cells (adjusted P  $2.01 \times 10^{-8}$ ), and  
186 NK cells (adjusted P 0.014) (**Supp. Table 5**). The leading-edge subset of genes that  
187 contributed to this term included *SGK1*, *GADD45B*, *MAFF*, *PDP1*, *ICAM1*, *TENT5A*, *HIF1A*,  
188 *TNF*, *ID3*, *CDKN1A*, *FOSB*, *HBEGF*, *NR4A3*, *VEGFA*, *BHLHE40*, *CXXC5*, *NOCT*, *IL1B*,  
189 *CXCL2* and *HSPA5* (**Fig. 2J**), many of which are cellular stress response genes. Analysis of



190 monocyte subsets using more fine-grained annotation, revealed enrichment of the pathway  
191 specifically in classical CD14 monocytes, and not in intermediate and non-classical CD16  
192 monocytes, suggesting the former was the source of the signal in monocytes. In the smaller  
193 2021 Cohort, where we had paired pre-infection and infection samples from the same  
194 individuals, we replicated the findings of significant enrichment of the “Orexin Receptor  
195 Pathway” in CD14+ CD16- monocytes and NK cells, but not in dendritic cells (**Supp. Table  
196 5**).

197  
198 Overall, our findings comparing COVID-19 positive and negative samples from ESKD patients  
199 are broadly similar to those described previously in other more general patient populations.  
200

### 201 **Immune cell transcriptomic correlates of COVID-19 severity in ESKD patients**

202  
203 We next assessed molecular and cellular changes associated with COVID-19 severity at the  
204 time of blood sampling, categorised as mild, moderate, severe, or critical (Methods). Analysis  
205 of cell type numbers comparing samples taken from patients at the time of severe or critical  
206 disease (hereafter ‘severe/critical’, n=56) to those taken at the time of mild or moderate  
207 disease (hereafter ‘mild/moderate’, n=84) revealed that the relative abundance of dividing B-  
208 ASC cells was increased in the severe/critical group (**Fig. 3A, Supp. Table 6**).

209  
210 We then performed differential gene expression within each cell type, again comparing  
211 samples taken at the time of severe/critical COVID-19 to mild/moderate COVID-19 (**Supp.  
212 Table 7**). Taking genes significantly associated with disease severity, we identified the  
213 corresponding biological pathways through enrichment analysis (**Fig. 3B, Supp. Table 8**).  
214 Where significant enrichment of pathways was identified within a cell type, we then used a  
215 more granular cell type annotation to delineate the source of the signal. We identified 86  
216 pathways that differentiated mild/moderate from severe/critical disease. The majority of these  
217 were in the B cell (35) or monocyte (29) compartment. 11 pathways were associated with  
218 severity in NK cells and 5 in gamma delta cells with only 2 enriched pathways in CD4+ helper  
219 T cells with none in CD8+ T cells. Similarly, at the single gene level, 205 genes distinguished  
220 mild/moderate from severe/critical disease. 125 of these were in all monocytes or  
221 CD14+CD16- classical monocytes and 21 were in B cell subsets (**Supp. Table 8**).

222  
223 In B cells, “Antibody secreting cells” and “Antibody secreting cells that produce IgA”, numerous  
224 pathways relating to cell division were enriched in severe/critical disease. This is likely to  
225 represent increased activation of the adaptive immune response in severe/critical disease and  
226 the initiation of a response to drive neutralising antibody production. In dividing antibody  
227 secreted cells (B\_ASC\_dividing) and switched memory B cells, increased interferon signalling  
228 pathways also distinguished severe/critical from mild/moderate disease (**Supp. Table 8**).

229  
230 In monocytes, differential gene expression analysis between mild/moderate and severe/critical  
231 samples revealed significant enrichment of numerous pathways, including the KEGG  
232 “Asthma” and “Graft Versus Host Disease”, “Leishmania Infection” and “Allograft Rejection”  
233 pathway terms (**Supp. Table 8**). Many genes in these pathways were downregulated in  
234 severe/critical relative to mild/moderate disease and their high enrichment scores are driven,  
235 in part, by the high representation of *HLA* genes in the pathways. This is likely to reflect the  
236 downregulation of MHC molecules on antigen presenting cells in severe COVID-19 that has  
237 been previously reported. We observed down-regulation of *HLA-DPB1*, *HLA-DPA1*, *HLA-*

238 *DRB1*, *HLA-DRA* and *HLA-DQA1* in all monocytes (**Fig. 3C**). This was accompanied by down-  
239 regulation of *CD163* as noted in other studies. We also noted up-regulation of genes  
240 previously associated with severity such as *S100A8*, *S100A9*, *S100A12* and *MCEMP1* (**Fig.**  
241 **3C**)<sup>12</sup>. In all monocyte subsets, the most differentially expressed gene between mild/moderate  
242 and severe/critical samples was *TNF*, encoding TNF- $\alpha$  (p-value  $6.4 \times 10^{-116}$ ) (**Supp. Table 7**).  
243 Unexpectedly, given its pro-inflammatory effects, *TNF* gene expression was lower in  
244 severe/critical disease. We hypothesised that this might be as a result of negative feedback  
245 from elevated TNF- $\alpha$  at the protein level. We therefore compared monocyte *TNF* gene  
246 expression levels to protein levels of plasma TNF- $\alpha$  measured using Olink immunoassays in  
247 the same set of samples. This revealed higher plasma TNF- $\alpha$  protein in samples taken at the  
248 time of severe/critical disease. Correlation analysis between plasma TNF- $\alpha$  protein monocyte  
249 *TNF* gene expression revealed a weak negative correlation (Pearson  $r$  -0.15), demonstrating  
250 an uncoupling of plasma protein and gene expression levels (**Fig. 3D**).

251  
252 Given the importance of monocytes in the host immune contribution to COVID-19 severity<sup>13</sup>,  
253 we performed a deeper analysis of specific subsets. In classical CD14+ monocytes, there was  
254 enrichment for the Reactome “MHC Class II Antigen Presentation”, KEGG “Type I Diabetes  
255 Mellitus” and “Graft Versus Host Disease” and Reactome “Interferon Gamma Signalling” in  
256 severe disease (**Supp. Table 8**). Many of these pathway terms were driven by genes  
257 encoding MHC class II molecules (**Supp. Fig. 2A-F**). Within CD14+ monocytes, there was  
258 also enrichment of the matrisome-associated pathway, including increased amphiregulin  
259 (*AREG*) gene expression (**Fig. 3E, Supp. Table 8**). We and others have previously reported  
260 *AREG* protein up-regulation in plasma in severe disease<sup>14,15</sup>. The present study suggests that  
261 CD14+ monocytes may contribute to this. The Reactome “Neutrophil Degranulation” module  
262 was also enriched in CD14+ monocytes in severe disease (**Supp. Table 8**). *PLAC8* is a  
263 leading-edge gene in this pathway. In our dataset, it is significantly more highly expressed in  
264 severe disease (**Fig. 3E, Supp. Table 7**). *PLAC8* over-expression makes cells, including  
265 immune cells, permissive for SARS-CoV-2 infection, and thus high expression of this molecule  
266 in patients with severe/critical disease may predispose them to worse outcomes<sup>16</sup>.

267 We also observed significant transcriptomic differences in NK cells between mild/moderate  
268 and severe/critical COVID-19. This included differential expression of genes relating to both  
269 TLR4 and TLR9 signalling pathways as well as those in the ‘Oncostatin M Pathway’ (**Supp.**  
270 **Tables 7-8**). We previously reported upregulation of plasma protein levels of Oncostatin M in  
271 severe COVID-19<sup>14</sup>. This cytokine is known to regulate IL-6 and GM-CSF production, which  
272 have been previously implicated as drivers of severe COVID-19<sup>17</sup>. In dendritic cells, the sole  
273 pathway significantly associated with severity was the ‘Orexin Receptor Pathway’ which  
274 displayed a negative enrichment score in severe disease (**Supp. Table 8**). This pathway was  
275 not significantly associated with severity in any other cell type, in contrast to the COVID-19  
276 positive versus COVID-19 negative ESKD patient analysis, where we observed significant  
277 enrichment of this patient across multiple cell types.

278  
279 In summary, mild/moderate and severe/critical disease were distinguished by transcriptional  
280 changes in numerous cell subsets. These were dominated by signals from B cell and  
281 monocyte subsets with a minor contribution from NK cells. By contrast, transcriptional changes  
282 in conventional alpha beta T cells were less able to distinguish mild/moderate and  
283 severe/critical disease.

284

## 285 **Temporal gene expression trajectories vary according to disease severity**

286

287 The host response to infection is a dynamic process involving both the innate and adaptive  
288 immune systems. To understand these temporal dynamics in COVID-19, we performed  
289 longitudinal analysis of our multi-omic data. Cell type composition analysis revealed that most  
290 cell subtypes displaying an interferon-stimulated gene expression signature were significantly  
291 increased within the first week following symptom onset, and then gradually reduced over time  
292 (**Fig. 4A**). We observed significant increases in the relative abundance of some cell types  
293 persisting into weeks 2 and 3 following symptom onset (switched memory B cells, CD14 and  
294 CD16 monocytes, DC3, NK and CD8+ CTLs). I B cells, NK cells, CD4+ helper T cells, I CD8+  
295 T cells, cytotoxic CD8+ T cells and Tregs were enriched in recovery samples. More generally,  
296 there was an increase in the relative abundance of adaptive immune cells over the course of  
297 the infection. As expected from a viral airway infection, compositions of antibody secreting B  
298 cells, predominantly of class-switched (IgG and IgA) antibody isotypes, were increased  
299 already in the first week after onset of disease, persisting for up to three weeks. Relative  
300 numbers of most CD4+ and CD8+ T cell subsets gradually decreased over time, with the  
301 exception of cycling CD4+ T cells (**Fig. 4A**).

302

303 We next assessed the temporal patterns of gene expression changes during COVID-19 in  
304 ESKD patients and how these vary according to overall clinical course (defined by peak illness  
305 severity, binarised as mild/moderate or severe/critical). To achieve this, we performed  
306 longitudinal modelling using a linear mixed model with a time x peak severity interaction term.  
307 To reduce dimensionality, we analysed genes grouped together as modules according to  
308 pathway terms, using the Hallmark, Reactome and KEGG databases. A pathway with a  
309 significant time x severity interaction indicates that the pathway has a different temporal profile  
310 in mild/moderate versus severe/critical COVID-19. Our analysis revealed 183 pathways with  
311 significant (FDR <0.05) time x severity interactions (**Supp. Table 9**). Notably, the majority of  
312 the significant time x severity interactions were in B cells, accounting for 143 of the 183  
313 significant pathways. Pathways in B cells and monocytes dominate those showing the 20 most  
314 significant time x severity interactions. The two pathways showing the most significant time x  
315 severity interaction were the interferon alpha and interferon gamma response in non-class  
316 switched memory B cells. Significant time x severity interactions for these pathways are also  
317 seen in B cells, class switched B memory cells, cytotoxic CD4+ T cells, NK cells, NK2 cells  
318 and NKT cells (**Supp. Table 9**). These results reflected quantitative differences in the temporal  
319 gradient of the interferon pathway response, with more severe COVID-19 disease showing  
320 higher interferon pathway response early in disease and a steeper decline over time (**Fig. 4B**).

321

322 In both CD14+ monocytes and B cells we found significant time x severity interactions for  
323 “allograft rejection” pathways’, and in CD14 monocytes for “graft versus host disease”,  
324 “asthma”, “type 1 diabetes” and “systemic lupus erythematosus”. Examination of the genes  
325 that make up these pathways revealed that these signals were largely driven by distinct  
326 temporal patterns of *HLA* expression in patients. In patients with a severe/critical clinical  
327 course, we observed steep downregulation of *HLA* class II gene expression over time,  
328 compared to either a relatively flat or mild upregulation in patients with a more benign course.  
329 *HLA* class I gene expression was higher in early disease in patients with severe/critical  
330 disease than in mild disease but fell further in late disease (**Fig. 4C and Supp. Fig. 3A**).  
331 Among other pathways that showed significant time x severity interactions, we noted the

332 “KRAS signalling up” and “MYC targets” in B cells only, likely reflecting time dependent  
333 changes in their proliferation during infection that vary according to severity (**Supp. Table 9**).

334

335 These results illuminate how modelling the temporal component provides additional insights  
336 by identifying time-dependent severity associations with gene expression that are not apparent  
337 in single time-point cross-sectional analyses. Thus, transcriptomic changes are dependent  
338 both on time and severity, and the interplay of two, underscoring the importance of serial  
339 sampling in gaining a complete picture of the host immune response in COVID-19.

340

### 341 **Longitudinal TCR dynamics**

342

343 Given the central role of T cells in antiviral adaptive immunity, we next evaluated clonal T cell  
344 dynamics of SARS-CoV-2 infection. The longitudinal nature of our study and single-cell  
345 resolution enabled us to be specific in determining paired-chain clones that expanded over  
346 the course of COVID-19. A total of 3,137 unique TCR clones that appeared in two or more  
347 serial samples from the same patient were used to quantify clonal expansion. To increase the  
348 probability of identifying TCR clones specific to SARS-CoV-2, we focused on clones that were  
349 not present in pre-infection samples, thereby limiting the presence of cross-reactive or  
350 bystander T cells. We found that 42% of clones sampled longitudinally had increased clonal  
351 frequency following day 10 after a positive swab, and that 23% showed a marked expansion  
352 where they increased after day 2 of the positive swab, and further after day 10 (**Fig. 4D, Supp.**  
353 **Fig. 3B-C, Methods**). To investigate whether these clonal expansions were directed against  
354 SARS-CoV-2, we cross-referenced SARS-CoV-2 specific TCR sequences from the VDJDB  
355 database<sup>18</sup> and measured the overlap with clones identified in more than one serial sample  
356 within an individual. Clones expanding after day 10 were significantly enriched in SARS-CoV-  
357 2 specific TCR alpha chains ( $p=0.0014$ , two-sided Mann-Whitney test, **Fig. 4E**) compared to  
358 their non-expanding counterparts, while those fulfilling the stricter dual criteria above had an  
359 almost two-fold increase in antigen-specific TCRs ( $p=0.006137$ , **Fig. 4F**). We next tested the  
360 relationship between magnitude of expansion of the longitudinally identified clones and SARS-  
361 CoV-2 specificity. The fastest expanding clones had the highest proportion of SARS-CoV-2  
362 specific TCR alpha chains (**Fig. 4G**), indicating that we are capturing the adaptive immune  
363 response to COVID-19. This SARS-CoV-2 specificity estimate is likely a lower bound to the  
364 true number, as experimental data from the database is based on assays with many fewer  
365 SARS-CoV-2 peptides than the number of naturally occurring viral antigens. Thus, of the  
366 expanding sequences that we recovered that do not match the database, many more are likely  
367 to be virus specific.

368

369 Further leveraging our single cell data, we looked for patterns in the TCRs of expanding clones  
370 that might be shared across donors. We applied the tool Cell2TCR<sup>19</sup> to our expanded clones  
371 (excluding MAIT cells, *Methods*) and found 99 public TCR motifs, where a public TCR motif  
372 denotes a group of clonotypes with sufficient sequence similarity to likely recognise the same  
373 epitope that was found in two or more patients. Moreover, six TCR motifs were shared  
374 between three donors and three motifs between four donors, a scenario which is highly  
375 unlikely for randomly sampled TCR clones and provides evidence of strong selective pressure  
376 on the adaptive immune response to a common pathogen (**Fig. 4H**). As we had recruited  
377 patients during two distinct phases of the pandemic, we hypothesised that certain TCR motifs  
378 might be specific to a particular viral strain and exhibit sharing only across donors from the  
379 same cohort (e.g. sampled in 2020 or 2021, respectively). Of the 99 public TCR motifs, 64%



380 had donors from a single cohort, including two motifs of **Fig. 4I** with four donors each.  
381 Furthermore, 18% of public motifs contained at least one SARS-CoV-2 specific TCR  
382 sequence, underscoring the sensitivity of this approach to analyse the antigen-specific  
383 response. Our findings are in strong agreement with evidence from a recent SARS-CoV-2  
384 Human Challenge Study<sup>19</sup>, involving deliberate infection of healthy individuals with SARS-  
385 CoV-2, which had shown that the antigen-specific response included convergent paired-chain  
386 immune receptor motifs. We thus replicate the challenge study results in the context of natural  
387 infection and in a larger cohort comprising a clinically relevant vulnerable group consisting of  
388 older individuals with underlying comorbidities, which included cases of severe/critical COVID-  
389 19.

390

391 As our data was longitudinal, we next investigated the presence of time-restricted, activated  
392 T cell types characterised in the context of COVID-19 by Lindeboom *et al*<sup>19</sup>. Activated T cell  
393 states were found to be indicative of *de novo* T cell activation and harbouring SARS-CoV-2  
394 specific TCR sequences. Application of the automated cell state annotation tool Celltypist<sup>9</sup>  
395 revealed 1,927 activated T cells, spanning the CD4+, CD8+, regulatory and MAIT cell  
396 compartments and found among 58 ESKD COVID-19 patients (**Supp. Fig. 3D**). When  
397 normalising the counts by cell type and sample numbers and aggregating across time points,  
398 we observed a striking lack of activated T cells in pre-pandemic as well as convalescent  
399 COVID-19 samples (**Fig. 4H**). While MAIT cells and regulatory T cells showed a relative  
400 enrichment during the first week after positive PCR test, most activated CD4+ and CD8+  
401 appeared only after 10 days. All activated T cell types remained detectable three weeks after  
402 positive PCR test but had mostly disappeared again by the time convalescent samples were  
403 taken, highlighting the transient nature of these cell states. Activated T cells were further over-  
404 represented among the most expanded clones (**Fig. 4J**). This is in line with results from the  
405 clinical trial in Lindeboom *et al*, where activated MAIT cells could be detected as early as 3  
406 days after exposure to the virus, and circulating activated T cell abundance peaked 10-14  
407 days after exposure to the virus, with return to baseline after 28 days<sup>19</sup>.

408

#### 409 **Corticosteroids induce dexamethasone-related monocytes in COVID-19**

410

411 By the time of the 2021 COVID-19 wave in the UK, glucocorticoid administration with  
412 dexamethasone had become standard clinical practice following randomised clinical trials  
413 demonstrating that it reduced mortality in patients with COVID-19 requiring supplemental  
414 oxygen<sup>3</sup>. Corticosteroids are known for their broad immunosuppressive effects through  
415 several different mechanisms, including inhibiting the release of proinflammatory cytokines<sup>20</sup>.  
416 *In vitro* experiments have suggested that monocytes and macrophages treated with  
417 glucocorticoids can exhibit both anti-inflammatory and inflammation-resolving properties<sup>21</sup>.  
418 The effect of corticosteroids on human immune responses at single cell level *in vivo* has not  
419 been studied. Of the 16 patients in the 2021 Cohort, 7 received steroid treatment (**Supp. Table**  
420 **1**). Patients receiving steroids all had a peak illness severity of severe or critical. This provided  
421 us with an opportunity to investigate the effects of steroids at the single cell transcriptomic  
422 level over the course of their treatment.

423

424 Whilst exploring the innate immune response, we isolated the monocyte compartment from  
425 the rest of the data and sub-clustered these cells. We identified the emergence of a subset of  
426 monocytes that were only seen in COVID-19 positive, severe/critical cases but not in patients  
427 with mild/moderate disease (**Fig. 5A-B**). These cells were clearly demarcated on UMAP plots

428 as a distinct population. Differential gene expression analysis between all subsets of  
429 monocytes showed this population had transcriptional similarities with monocytes treated *ex*  
430 *vivo* with dexamethasone<sup>22</sup> (**Fig. 5C**). Compared to classical CD14 monocytes and IFN  
431 stimulated CD14 monocytes, the dexamethasone-related monocytes (Dex. mono) had lower  
432 expression of markers of inflammation such as *JUN* and *CXCL8* as well as lower expression  
433 of antigen presenting markers *HLA-DRA* and *HLA-DRB5*. Conversely, they showed higher  
434 expression of genes relating to anti-inflammatory actions (*CD163* and *ADAMTS2*), anti-  
435 oxidation (*SLC1A3* and *SESN1*), migration (*FPR1* and *MTSS1*) and phagocytosis (*MFGE8*  
436 and *MRC1*) (**Fig. 5C**). Notably, these cells were only present in patients recruited in the 2021  
437 Cohort, suggesting they were a direct effect of glucocorticoid treatment and not a  
438 consequence of severe COVID-19 itself (**Fig. 5A**).

439  
440 We formally tested the effect of glucocorticoids on differential cell abundance across the  
441 monocyte clusters using MiloR, accounting for time from infection<sup>23</sup>. We noted that both CD14  
442 monocytes and the dex. monos were significantly enriched after glucocorticoid treatment, and  
443 the IFN-stimulated CD16 monocytes, C1 CD16 monocytes and IFN-stimulated CD14  
444 monocytes were significantly enriched before treatment (**Fig. 5D**). Using the longitudinal data  
445 from only the individuals who were given glucocorticoid treatment, we evaluated the  
446 percentage of different monocyte subsets prior to and in the days after treatment. We found  
447 that, after glucocorticoid administration, there was a trend towards an increased relative  
448 abundance of the dex. monos and CD14 monocytes, whilst there was a decrease in both IFN-  
449 stimulated monocyte populations (**Fig. 5E**). No trends were observed in other cell types  
450 (**Supp. Fig. 4 and 5**). These results suggest that, along with promoting the emergence of the  
451 dex. monos, glucocorticoids could facilitate a reduction of the abundance of interferon-  
452 stimulated monocytes in severe COVID-19 infection.

453  
454 The dex. monos displayed high RNA and protein expression of CD163 (**Fig. 5C and 5F**) a  
455 scavenger receptor that is frequently used to mark 'alternatively activated' or 'M2'-like  
456 macrophages<sup>24</sup>. These macrophages possess regulatory functions which can suppress  
457 immune responses and reduce inflammation<sup>25</sup>. Macrophages treated with glucocorticoids  
458 have been shown to drive the polarisation of macrophages towards an 'alternatively  
459 activated'/M2-like phenotype<sup>26</sup>. These findings prompted us to further assess transcriptional  
460 programs of the dex. monos. We performed pathway enrichment analysis on all monocytes  
461 based on 15 different macrophage stimulation signatures<sup>27</sup>. The dex. monos were more  
462 associated with transcriptomic patterns associated with stimulation with IL-13, IL-4, ultra-pure  
463 LPS+immune complex, glucocorticoid stimulation, supporting their similarity to M2-like  
464 macrophages (**Fig. 5G**). The temporal emergence of the dex. monos and their presence only  
465 in the 2021 Cohort strongly suggest that the changes we observed were driven by  
466 dexamethasone treatment rather than disease severity.

## 467 468 **Discussion**

469  
470 Here, we performed CITE-seq and immunoreceptor profiling in ESKD patients with COVID-19  
471 to longitudinally profile the circulating immune cell changes associated with COVID-19 in two  
472 temporally distinct cohorts. A unique aspect of our study was the 2021 cohort, where we  
473 obtained longitudinal PBMC samples from patients with COVID-19 who were originally  
474 sampled as COVID-19 negative controls during 2020 but subsequently became infected  
475 during 2021. As a result, we were able to perform intra-individual analysis of the host immune

476 cell PBMC transcriptome comparing pre-infection with acute infection, thus minimising the  
477 impact of confounding factors. Another strength of our study was the inclusion of patients of  
478 diverse ancestries.

479

480 Using a multi-omic approach, we identified COVID-19-associated changes in the cellular  
481 composition of PBMC in ESKD patients including increased relative abundance of naive B  
482 cells and a decreased relative abundance of total monocytes, CD8+ memory and CD4+ CTL  
483 T cells. This decrease in the relative numbers of circulating monocytes following infection was  
484 also observed in a recent experimental medicine challenge study, involving deliberate infection  
485 of healthy individuals with SARS-CoV-2<sup>19</sup>. COVID-19 was associated with widespread  
486 transcriptomic changes in a wide variety of cell types. Many of these reflect the activation of  
487 inflammatory pathways, including the type 1 interferon pathway and cellular activation and  
488 proliferation. Overall, the COVID-19-associated changes in ESKD patients were similar to  
489 those reported in other studies, but we did identify some changes that, to our knowledge, have  
490 not been previously reported. For example, gene expression pathway analysis highlighted  
491 significant negative enrichment of the "Orexin Receptor Pathway" in COVID-19 positive ESKD  
492 patients versus uninfected ESKD patients across several innate immune cell types. Many of  
493 the leading-edge genes contributing to the "Orexin receptor pathway" term are also involved  
494 in other pathways, which makes interpretation of this finding more challenging. Orexin receptor  
495 signalling is well-characterised in neurological diseases such as narcolepsy, but there is also  
496 evidence that Orexins can have immunological effects that may be relevant in the context of  
497 COVID-19<sup>28,29</sup>.

498

499 We also identified numerous pathways associated with COVID-19 severity in ESKD,  
500 particularly in monocytes and B cells. Notably, we found many more pathways associated with  
501 severity in B cells than in T cells. In addition, severe COVID-19 was associated with a higher  
502 relative abundance of antibody-secreting B cells and with higher expression of genes involved  
503 in cell division. In CD14+CD16- monocytes, we observed elevated *PLAC8* expression in  
504 severe COVID-19. High *PLAC8* expression makes lung cells more permissive for SARS-CoV-  
505 2 infection *in vitro*<sup>16</sup>. In line with this, a genome-wide CRISPR knockout screen identified  
506 *PLAC8* as an essential factor for infection with a different coronavirus, swine acute diarrhoea  
507 syndrome coronavirus (SADS-CoV)<sup>30</sup>. While SARS-CoV-2 predominantly infects epithelial  
508 cells, it has also been detected in macrophages and T cells<sup>31</sup>. Together with this work on the  
509 cell biology of *PLAC8* in viral infection, our observation that expression changes with disease  
510 severity in monocytes raises the possibility that modulating *PLAC8* expression may provide a  
511 therapeutic opportunity to prevent infection of both epithelial and immune cells.

512

513 Multi-omic measurements allowed us to identify instances of negative correlation between  
514 immune cell gene expression and levels of the corresponding plasma protein. For example, in  
515 severe COVID-19 the most down-regulated gene in monocytes was *TNF* (encoding TNF-  
516 alpha), yet conversely, TNF-alpha was significantly upregulated in the plasma from the same  
517 blood draw. Potential explanations for this uncoupling include negative feedback, or that other  
518 cell types could be contributing to circulating TNF-alpha pool (e.g. endothelial cells, tissue  
519 macrophages). This observation underlines the complementary value of combining multi-omic  
520 data, since plasma proteins reflect protein production by a wide variety of tissues other than  
521 blood cells<sup>32</sup>. Since our data are observational, we cannot determine if elevated circulating  
522 TNF-alpha is a cause or a consequence of severe COVID-19. Nevertheless, since TNF-alpha  
523 blocking drugs are in routine clinical use in inflammatory diseases such as rheumatoid arthritis,

524 our results suggest there may be value in evaluating the repurposing of these medications for  
525 COVID-19<sup>33</sup>.

526  
527 Longitudinal analysis of changes in cell type abundance showed a peak in cells showing an  
528 interferon-activated gene signature in the first week of illness followed by a waning, again  
529 consistent with that seen in other work<sup>19</sup>. Gene expression pathways which displayed distinct  
530 temporal profiles according to clinical severity were predominantly found in B cells and  
531 monocytes.

532  
533 Longitudinal analysis also revealed the time-restricted appearance and expansion of T cells  
534 with likely SARS-CoV-2 specificity. Leveraging the large number of longitudinal samples, we  
535 identified the emergence of public T cell clones with a restricted TCR repertoire that are shared  
536 across patients. Cross-referencing the TCRs with SARS-CoV-2 specific databases, we found  
537 most matches among T cells that strongly expand in the days following a positive PCR test,  
538 and a significant enrichment of matches compared to pre-pandemic samples. Our results  
539 support the hypothesis that both TCR chains together determine antigen specificity, which we  
540 were able to capture jointly using single-cell sequencing, as expanding clones could further  
541 be grouped into shared TCR motifs with high sequence similarity in both chains. In addition, a  
542 recently activated T cell phenotype is overrepresented in that same population. We expand  
543 on existing knowledge from the first human COVID-19 challenge study by analysing a larger  
544 patient cohort, which included cases of severe disease, as well as replicating several key  
545 findings in the context of natural infection. In addition, we identified longitudinal expansion of  
546 some clones that are not recorded as SARS-Cov2-specific in the VDJDDB database. These  
547 could potentially be previously undescribed SARS-CoV2-specific T cells, given that we  
548 analysed a large number of longitudinal samples that included patients with severe/critical  
549 disease and also diverse ancestry. An alternative explanation is that the expansion of some  
550 TCR clones was driven by bystander activation secondary to the inflammatory milieu. Thus,  
551 our study generates hypotheses for further functional work.

552  
553 An important finding of this study was the identification of a distinct population of monocytes  
554 that emerged after glucocorticoid therapy. These were not observed in any patients in the  
555 2020 Cohort, before the introduction of glucocorticoid therapy as standard of care, and their  
556 emergence in the 2021 Cohort occurred rapidly after glucocorticoid administration. These  
557 findings could have implications beyond COVID-19. Corticosteroids are frequently used to  
558 suppress inflammation and they have pleiotropic effects on immunity that are not fully  
559 understood despite their long-standing clinical use. Therefore, being able to probe the effects  
560 of steroid treatment in humans using single cell resolution multi-omic technologies provides  
561 potential insights into their mode of action. This may facilitate rational drug design of  
562 compounds that target these pathways without steroid side effects. Here, we demonstrated  
563 that glucocorticoids could promote the emergence of a transcriptionally distinct subpopulation  
564 of monocytes. An outstanding question remains the functional properties of these steroid-  
565 induced cells such as their ability to traffic to tissues and modulate inflammatory responses.

566  
567 ESKD patients have increased susceptibility to sepsis and impaired vaccination response (for  
568 example, hepatitis B vaccination)<sup>8,34</sup>. Reports on neutralising activity against the delta variant  
569 following SARS-Cov-2 vaccination showed an impaired response of haemodialysis patients  
570 compared with healthy controls in response to the AZD1222 vaccine<sup>35</sup> and an impaired  
571 neutralising response to the omicron variant with heterologous boost regimes consisting of



572 two doses of the AZD1222 followed by the mRNA vaccine BNT162b2<sup>36</sup>. Vaccination strategies  
573 have been very successful in reducing morbidity and mortality, but widespread transmission  
574 of SARS-CoV-2 continues. As new variants emerge, certain patient groups, such as those  
575 with ESKD will have a higher risk of both contracting infection and of experiencing a severe  
576 disease course, underscoring the importance of studying such patient groups.

577

578 Our study has some limitations. Our data are observational and thus cannot delineate whether  
579 changes in cell populations or gene expression are pathogenic drivers or downstream  
580 consequences of the systemic inflammatory response. Observational data are also vulnerable  
581 to the effects of confounding factors. Our use of paired pre-infection and infection samples in  
582 the analysis of the Wave 2 partially mitigates this, but unknowable confounders such as viral  
583 exposure at the time of infection may nevertheless impact the magnitude of the host immune  
584 response. In addition, we studied peripheral blood immune cells due to accessibility, but these  
585 may not always reflect those at the site of tissue inflammation. We did not have a comparator  
586 group of ESKD patients with another infection, so we cannot determine whether the changes  
587 we observed are specific to COVID-19. Finally, this was a single centre study.

588

589 In summary, we characterised the longitudinal host immune response in COVID-19 in a  
590 clinically vulnerable group through multi-omic technologies. These data illuminate the  
591 temporal dynamics of the response to infection, and how these diverge in mild versus severe  
592 disease. Our results reveal the impact of glucocorticoid therapy, with the emergence of a  
593 specific monocyte subpopulation following treatment. The data here will provide a valuable  
594 resource for the research community.

595

### 596 **Acknowledgements**

597 This work was funded by a UKRI-DHSC COVID-19 Rapid Response Rolling Call  
598 (MR/V027638/1) (to J.E.P.), funding from the UK Coronavirus Immunology Consortium (UK-  
599 CIC) and Wellcome Human Cell Atlas Strategic Science Support (WT211276/Z/18/Z), and the  
600 NIHR Imperial Biomedical Research Centre (BRC). The views expressed are those of the  
601 authors and not necessarily those of the NIHR or the Department of Health and Social Care.  
602 M.H. is funded by Wellcome (221052/Z/20/Z, 215116/Z/18/Z), the Lister Institute for  
603 Preventive Medicine, and NIHR and Newcastle Biomedical Research Centre. L.M.D is  
604 supported by the European Union's Horizon 2020 research and innovation programme under  
605 the Marie Skłodowska-Curie grant agreement No 955321. J.E.P. is supported by a fellowship  
606 from the Medical Research Foundation (MRF-057-0003-RG-PETE-C0799). M.C.P. is a  
607 Wellcome Trust Senior Fellow in Clinical Science (212252/Z/18/Z). C.L.C was supported by  
608 an Auchi Clinical Research Fellowship.

609

### 610 **Author contributions**

611 Conceptualisation, M.B., S.A.T, M.H, M.R.C, J.E.P; Investigation, E.St., N.B.B, M.C, A.P.,  
612 E.P., T.M and A.P. ; Methodology, J.R.F, B.J.S., J.G., Resources, C.L.C., N.M-T., M.P. S.M.,  
613 M.W. and E.Sa. ; Formal analysis, E.St., E.M-D., L.M.D., R.G.H.L., Z.K.T., W.M.T., S.B. and  
614 D.C.T.; Writing, E.St., E.M-D., L.M.D., R.G.H.L., Z.K.T., W.M.T., D.C.T. and J.E.P.; Editing:  
615 M.C.P., M.B., S.A.T., M.H. and M.R.C.; Supervision, M.B., S.A.T., M.H., M.R.C, D.C.T. and  
616 J.E.P.

617

618

619

620 **Declaration of interests**

621 S.A.T is on the advisory board for Cell Genomics. L.M.D., R.G.H.L. and S.A.T. are inventors  
622 on a filed patent that is related to the detection and application of activated T cells. In the past  
623 three years, S.A.T. has received remuneration for Scientific Advisory Board Membership from  
624 Sanofi, GlaxoSmithKline, Foresite Labs and Qiagen. S.A.T. is a co-founder and holds equity  
625 in Transition Bio and Ensocell. From 8 January 2024, S.A.T is a part-time employee of  
626 GlaxoSmithKline. The other authors have no conflicts of interest.

627  
628 **Supplemental information**

629 Figures S1-S6 and Tables S1-S9.

630

631 **Figure Legends**

632

633 **Fig. 1: Study Overview.**

634 **A)** Schematic of the study design showing the recruitment of both cohorts and how their  
635 samples were processed in the laboratory then analysed. Neg. control = COVID-19 negative  
636 ESKD patient. Figure created using Biorender.com. **B)** Timing of blood sampling in relation to  
637 illness onset. Colours indicate the COVID-19 severity over time. 'X' with an adjacent arrow  
638 indicates death during the hospital admission occurring at >30 days. **C)** UMAP showing the  
639 detailed annotations of B cells, myeloid and progenitors and T cells, respectively. ASDC = Axl  
640 Siglec dendritic cell, MAIT = mucosal-associated invariant T cell, ASC = antibody secreting  
641 cell, sw. mem. = switched memory, CTL = cytotoxic T lymphocyte, T g/d = gamma delta T cell,  
642 EMRA = terminally differentiated effector memory T cell, ILC = innate lymphoid cell, mono =  
643 monocyte, int. = intermediate.

644

645 **Fig. 2: Cell type abundance and DEG/pathway analysis for positive cases versus**  
646 **negative controls.**

647 **A-H)** Bar charts displaying relative numbers of cells that significantly changed in abundance  
648 in week 1 of COVID-19 infection compared to a control group of COVID-19 negative ESKD  
649 patients. \* $P \leq 0.05$ , \*\* $P \leq 0.01$ , \*\*\* $P \leq 0.001$ . **I)** Heatmap of gene expression pathways  
650 significantly (FDR <0.05) associated with COVID-19 positivity. Cell labels above plot denote  
651 broad cell annotations and labels below denote more granular cell annotations. R = reactome,  
652 WP = wiki pathways, K = KEGG, NABA = Alexandra Naba and PID = pathway interaction  
653 database. **J)** Dot plot displaying the expression of the leading-edge subset of genes that  
654 contributed to the term "Orexin Receptor Pathway" for COVID positive and negative patients.  
655 Mono = monocytes.

656

657 **Fig. 3: Cell type abundance and DEG/pathway analysis for severity of positive cases.**

658 **A)** Bar chart displaying the relative abundance of dividing antibody secreting B cells for mild  
659 and moderate patients compared to severe and critical patients.  $P = 0.017$  **B)** Heatmap of  
660 pathways significantly (FDR <0.05) associated with COVID-19 severity. Cell labels above plot  
661 denote broad cell annotations and labels below denote more granular cell annotations. R =  
662 reactome, WP = wiki pathways, K = KEGG and PID = pathway interaction database. **C)** Dot  
663 plot displaying the expression of differentially expressed genes relating to severity in all  
664 monocyte populations. **D)** Left: Boxplots of *TNF* RNA counts in monocytes from the scRNA-  
665 seq dataset and normalised plasma TNF- $\alpha$  protein abundance measured with Olink  
666 immunoassays (n=57 samples from 21 individuals with both RNA and plasma protein levels  
667 measured). Right: correlation between *TNF* gene expression and TNF- $\alpha$  plasma protein levels.

668 (Pearson  $r = -0.15$ ) **E**) Left: dot plot displaying gene expression of *AREG* in CD14+ monocytes  
669 stratified according to COVID-19 severity at the time of sampling. Right: dot plot displaying  
670 gene expression of *PLAC8* in CD14+, CD16+ and intermediate monocytes split, again  
671 stratified according to COVID-19 severity.

672

#### 673 **Fig. 4: Longitudinal gene expression and TCR trajectories**

674 **A**) Dot plots displaying the significant cell type abundance changes across COVID-19 infection  
675 compared to pre-infection samples for cells that have an interferon and non-interferon  
676 stimulated counterpart. Time since onset of disease is either time since display of first  
677 symptom or positive test (whichever is earliest). **B**) Estimated marginal mean of the effect of  
678 time from infection by severity group for the expression of IFN alpha and IFN gamma pathway  
679 genes for cell types with significant time x severity interaction. Time since onset of disease is  
680 either time since display of first symptom or positive test (whichever is earliest). **C**) Heatmap  
681 displaying 10 genes from multiple pathways (Allograft rejection, Asthma, Graft versus host  
682 disease, Type 1 diabetes, and Systemic Lupus Erythematosus) that had a significantly  
683 different temporal profile in mild vs severe disease (linear mixed model, FDR < 0.05) in CD14  
684 monocytes. Colour indicates LMM estimated marginal means over time, stratified by patient  
685 group ( $n = 130$  samples from 37 individuals). Genes are clustered based on the temporal  
686 profile of the discordance between mild/moderate and severe/critical disease. Time since  
687 onset of disease is either time since display of first symptom or positive test (whichever is  
688 earliest). **D**) Absolute numbers of clones considered for longitudinal analysis and expanded  
689 clone counts. **E**) Proportion of SARS-CoV-2 specific clones among all clones, stratified by  
690 whether the clone expanded after day 10 following positive PCR test. Specificity was  
691 determined as a perfect match with a TCR alpha chain from the SARS-CoV-2 database  
692 VDJDDB. Significance with two-sided Mann-Whitney test:  $p = 0.0014$ . **F**) As for (C) but stratifying  
693 by whether a clone was expanded after day 2 and further after day 10. **G**) SARS-CoV-2  
694 specific clone proportion among fastest increasing clones. Clones were sorted by decreasing  
695 expansion magnitude pre/post day 10 following positive PCR test (*Methods*). Baseline of  
696 matches with database from pre-pandemic samples shown in dashed line. Specificity was  
697 determined as a perfect match with a TCR alpha chain from the SARS-CoV-2 database  
698 VDJDDB. **H**) Sequence logos of 3 most shared paired-chain TCR motifs, with number of  
699 individuals and number of unique clones sharing the motif mentioned. Letter height indicates  
700 frequency of AA at that position across T cells pertaining to the motif. AAs are coloured by  
701 side chain chemistry: Acidic (red), basic (blue), hydrophobic (black), neutral (purple), polar  
702 (green). AA: amino acid. **I**) Distribution of predicted activated T cells across days since positive  
703 swab result. T cell counts were normalized by number of cells and samples, cell states were  
704 predicted using Celltypist (*Methods*). **J**) Activated T cell state proportion among fastest  
705 increasing clones. Clones were sorted by decreasing expansion magnitude pre/post day 10  
706 following positive PCR test (*Methods*). Baseline proportion of activated T cells from pre-  
707 pandemic samples shown in dashed line.

708

#### 709 **Fig. 5: Dexamethasone treatment promotes steroid associated monocytes**

710 **A**) UMAPs displaying all subsets of monocytes; coloured by subset (top), patient cohort  
711 (bottom left), COVID-19 status (bottom middle) and severity (bottom right). **B**) Bar charts  
712 displaying proportions of all monocytes grouped by mild/moderate and severe/critical severity.  
713 **C**) Dot plots displaying gene expression (left) and protein expression (right) in CD14  
714 monocytes, IFN-stimulated CD14 monocytes and the dexamethasone associated monocytes  
715 (Dex. mono). **D**) Beeswarm plot displaying the differential abundance of monocyte subsets for

716 samples from patients that were administered steroids, before and after treatment. **E)** Line  
717 charts displaying the percentage of monocyte subsets across the days before and after  
718 administration of steroids. Line colours represent different patients. **F)** Dot plot displaying the  
719 expression of monocyte marker genes in all monocyte subsets. **G)** Heat map displaying gene  
720 module scores for CD14 monocytes, IFN-stimulated CD14 monocytes and the  
721 dexamethasone associated monocytes (Dex. mono).

722

### 723 **Supplementary Figure 1: Cell demultiplexing and annotation**

724 A. Heat map showing the overlap of manual versus predicted cell annotations. B. Dot plots  
725 displaying gene (top) and protein (bottom) expression of markers for myeloid and  
726 haematopoietic cells. C. Dot plots displaying gene (top) and protein (bottom) expression of  
727 markers for B cells. D. Dot plots displaying gene (top) and protein (bottom) expression of  
728 markers for T and innate lymphoid cells.

729

### 730 **Supplementary Figure 2: Expression of genes contributing to pathways in CD14 731 monocytes and B cells**

732 A. Dot plot displaying the expression of genes that contribute to the Kegg ‘Systemic Lupus  
733 Erythematosus’ pathway in CD14 monocytes. B. Dot plot displaying the expression of genes  
734 that contribute to the Kegg ‘Type 1 Diabetes Mellitus’ pathway in CD14 monocytes. C. Dot  
735 plot displaying the expression of genes that contribute to the Kegg ‘Asthma’ pathway in CD14  
736 monocytes. D. Dot plot displaying the expression of genes that contribute to the Kegg ‘Graft  
737 Versus Host Disease’ pathway in CD14 monocytes. E. Dot plot displaying the expression of  
738 genes that contribute to the Kegg ‘Allograft rejection’ pathway in CD14 monocytes. F. Dot plot  
739 displaying the expression of genes that contribute to the Kegg ‘Allograft rejection’ pathway in  
740 B cells.

741

### 742 **Supplementary Figure 3: Longitudinal analysis**

743 A. Clonal frequency dynamics for all clones expanded after day 2 post positive PCR result, as  
744 well as a trendline. B. Clonal frequency dynamics for all clones expanded after day 2 post  
745 positive PCR result and further expanded after day 10, as well as a trendline. C. Number of  
746 activated T cells according to Celltypist predictions, split by T cell type.

747

### 748 **Supplementary Figure 4: Trend of cell proportions during steroid treatment**

749 Line charts displaying the percentage of cell subsets across the days before and after  
750 administration of steroids. Line colours represent different patients.

751

### 752 **Supplementary Figure 5: Trend of cell proportions during steroid treatment**

753 Line charts displaying the percentage of cell subsets across the days before and after  
754 administration of steroids. Line colours represent different patients.

755

### 756 **Supplementary Figure 6: Estimated ancestry calculated using genotype compared to 757 self-reported by patient.**

758 A. PCA plot of genetically estimated ancestry of each patient calculated using genotypes. B.  
759 PCA plot of the ancestry reported by the patients themselves.

760

### 761 **Supplementary Table 1: Metadata from individuals sampled.**

762

### 763 **Supplementary Table 2: List of antibodies included in the Total-seq panel.**



764

765 **Supplementary Table 3:** Statistical tests from cell abundance analysis of cases versus  
766 controls.

767

768 **Supplementary Table 4:** Differentially expressed genes for each cell type for cases versus  
769 controls.

770

771 **Supplementary Table 5:** Gene set enrichment pathway analysis for each cell type based on  
772 DEGs from Supp. Table 4.

773

774 **Supplementary Table 6:** Statistical tests from cell abundance analysis of severity.

775

776 **Supplementary Table 7:** Differentially expressed genes for each cell type for severity.

777

778 **Supplementary Table 8:** Gene set enrichment pathway analysis for each cell type based on  
779 DEGs from Supp. Table 7.

780

781 **Supplementary Table 9:** Gene set enrichment pathway analysis of time x severity  
782 interactions.

783

## 784 **Materials and Methods**

785

### 786 **Ethical approval**

787

788 All participants (patients and controls) were recruited from the Imperial College Healthcare  
789 NHS Trust Renal and Transplant Centre and its satellite dialysis units, London, United  
790 Kingdom, and provided written informed consent prior to participation. Study ethics were  
791 reviewed by the UK National Health Service (NHS) Health Research Authority (HRA) and  
792 Health and Care Research Wales (HCRW) Research Ethics Committee (reference  
793 20/WA/0123: The impact of COVID-19 on patients with renal disease and immunosuppressed  
794 patients). Ethical approval was given.

795

### 796 **Patient cohorts**

797

798 We recruited two cohorts of ESKD patients with COVID-19. All patients were on haemodialysis  
799 prior to acquiring COVID-19. The first cohort ('2020/Wave 1') were recruited during the initial  
800 phase of the COVID-19 pandemic (April-May 2020). We collected 61 serial blood samples  
801 during acute infection for 21 patients with COVID-19. Three samples were collected for 19 of  
802 these patients; two samples were collected for the other two individuals. We also  
803 contemporaneously recruited 37 non-infected ESKD patients on haemodialysis to provide a  
804 control group.

805

806 The second cohort ('2021/Wave 2') were recruited during the resurgence of cases in January-  
807 March 2021. This cohort, which consisted of 16 ESKD patients with COVID-19, had all been  
808 recruited as part of the COVID-19 negative control group during the 2020 wave, and so a pre-  
809 infection sample collected in April/May 2020 (8-9 months preceding infection) was also  
810 available for 13 patients. For these patients, samples were systematically acquired at regular  
811 intervals (median 5 samples per patient, collected every 2-3 days over the course of the acute

812 infection). Additionally, for 10 of these 16 patients, we acquired convalescent samples  
813 approximately 2 months following the acute COVID-19 episode. 3 individuals in this cohort  
814 had received one dose of the COVID-19 vaccine, however their first blood sample was taken  
815 within an average of 5 days so there was an unlikely chance this had an effect on their immune  
816 response to the infection.

817

### 818 **Clinical severity scores**

819

820 Severity scoring was performed based on WHO classifications (WHO clinical management of  
821 COVID-19: Interim guidance 27 May 2020) adapted for clinical data available from electronic  
822 medical records. 'Mild' was defined as COVID-19 symptoms but no evidence of pneumonia  
823 and no hypoxia. 'Moderate' was defined as symptoms of pneumonia or hypoxia with oxygen  
824 saturation (SaO<sub>2</sub>) greater than 92% on air, or an oxygen requirement no greater than 4 L/min.  
825 'Severe' was defined as SaO<sub>2</sub> less than 92% on air, or respiratory rate more than 30 per  
826 minute, or oxygen requirement more than 4 L/min. 'Critical' was defined as organ dysfunction  
827 or shock or need for high dependency or intensive care support (i.e. the need for non-invasive  
828 ventilation or intubation). Severity scores were charted throughout a patient's illness. We  
829 defined the overall severity/clinical course for each patient as the peak severity score that  
830 occurred during the patient's illness.

### 831 **PBMC isolation protocol**

832 Peripheral blood mononuclear cells (PBMCs) were obtained by density gradient centrifugation  
833 using Lymphoprep (STEMCELL Technologies, Canada). Approximately 20 ml of blood were  
834 diluted 1x with phosphate buffered saline (PBS) with addition of 2% fetal bovine serum (FBS)  
835 and layered on top of 15 ml of Lymphoprep solution. The samples were then centrifuged at  
836 800 g for 20 min at room temperature without break. PBMCs were collected from the interface  
837 and washed twice with PBS/2%FBS. PBMCs were cryopreserved in 1 ml freezing medium  
838 (FBS 10% DMSO) and stored in liquid nitrogen.

### 839 **PBMC processing and CITEseq**

840

#### 841 ***Samples collected during 2020 wave***

842 Frozen PBMCs were thawed by adding a small volume of ice-cold PBS to PBMC samples and  
843 transferred to a falcon tube containing 35 mL of ice-cold PBS. Samples were then centrifuged  
844 and counted. Dead cells were removed using the EasySep Dead Cell Removal kit (Stem Cell  
845 Technologies) according to the manufacturer's protocol. Cells were then counted again and  
846 40,000 cells from each sample were pooled together in batches of seven with the aim for each  
847 pool to contain ~300,000 cells, ensuring each pool had a different combination of genotypes  
848 for simple demultiplexing. Pooled cells were then stained with Fc Receptor Blocking Solution  
849 (Biolegend) and then with TotalSeq™-C Human Universal Cocktail V1.0 (Biolegend)  
850 according to the manufacturer. Cells were then washed once with PBS and then counted.  
851 Each pool was loaded across two channels of a Chromium Chip (10x Genomics), using Single  
852 Cell 5' V2 kits, to achieve a recovery of 10,000 cells per sample.

853

#### 854 ***Samples collected during 2021 wave***

855 Frozen PBMCs were thawed at 37°C until a small ice crystal remained. Samples were then  
856 transferred to another tube and ten times the volume of pre-warmed RF-10 media (RPIM

857 (Sigma) supplemented with 10% (v/v) fetal calf serum (Life technologies), 100U/ml Penicillin  
858 (Sigma), 100 µg/ml Streptomycin (Sigma) and 1% (v/v) L-Glutamine) was added dropwise.  
859 Cells were then centrifuged and counted. Dead cells were removed using the EasySep Dead  
860 Cell Removal kit (Stem Cell Technologies) according to the manufacturer's protocol. Cells  
861 were then counted again and 250,000 cells from each sample were pooled together in batches  
862 of four using a leave-one-out strategy for simple demultiplexing. Pooled cells were then  
863 stained with Fc Receptor Blocking Solution (Biolegend) and then with TotalSeq™-C Human  
864 Universal Cocktail V1.0 (Biolegend) according to the manufacturer. Cells were then washed  
865 three times with Flow Buffer (Dulbecco's phosphate buffered saline (PBS)(Sigma)  
866 supplemented with 2% (v/v) FCS and 2mM EDTA (Sigma)) and then counted. Each pool was  
867 loaded across two channels of a Chromium Chip (10x Genomics), using Single Cell 5' V2 kits,  
868 to achieve a recovery of 10,000 cells per sample.

869

### 870 **Library Preparation and Sequencing**

871

872 Gene expression, cell surface protein, TCR and BCR libraries were generated according to  
873 the manufacturer's protocols. All libraries were sequenced using a NovaSeq 6000 to achieve  
874 a minimum of 20,000 reads per cell for gene expression libraries and 5,000 reads for cell  
875 surface protein, TCR and BCR libraries.

876

### 877 **Bioinformatics Pre-processing**

878

879 We jointly aligned the antibody-derived tags (ADT) and gene expression libraries from CITE-  
880 seq experiments using *CellRanger 4.0*, using the reference 10X Genomics provided with the  
881 release of *CellRanger 3.0*, and the ADT barcode reference provided by the supplier. Single  
882 cell TCR and BCR sequencing data was aligned using *CellRanger 4.0* using the GRCh38 VDJ  
883 reference provided by 10X Genomics. We used *Seurat V4.1.0*<sup>37</sup> to import gene expression  
884 and ADT counts. Low quality cells were excluded by removing droplets with either fewer than  
885 1000 RNA UMIs, or fewer than 200 RNA features detected, or with more than 10% of their  
886 RNA UMIs mapping to mitochondrial genes. *SoupX*<sup>38</sup> was used to remove signals from  
887 ambient RNA and background antibody staining. SoupX parameters 'soupQuantile' and  
888 'tfidfMin' were set to 0.25 and 0.2, respectively, and lowered by decrements of 0.05 until the  
889 contamination fraction was calculated using the 'autoEstCont' function. Corrected gene  
890 expression and ADT counts were then scaled to 10000 UMIs per cell and log1p transformed.

891

### 892 **Sample demultiplexing**

893 We used *souporcell v2.0*<sup>39</sup> to perform genotype-based demultiplexing of pooled PBMC  
894 libraries to assign donor identifiers to each single cell transcriptome. To ensure high  
895 reproducibility of the genotype-decomposition, we merged the sequencing data from each set  
896 of replicates of the same donor pool prior to *souporcell* analysis. We used *pysam v0.17.0* to  
897 amend cell barcodes with original library identifiers and to merge bam files. Using the merged  
898 bam files, we ran *souporcell* using the provided set of common variants, with remapping  
899 disabled and with the appropriate number of expected genotypes. To assign a donor identifier  
900 to each *souporcell* genotype cluster we leveraged the pooling strategy of donors per library  
901 which was designed in such a way that every donor was present in a unique combination of  
902 pools. We used the *cardelino* R package<sup>40</sup> to import genotypes and perform pairwise  
903 comparisons of all identified *souporcell* genotype clusters, to identify highly similar genotype  
904 clusters in different pools that likely originated from the same donor, which was then given a

905 donor label based on the combination of pools in which the genotype was detected. Genotypes  
906 that were not resolvable due to missing or low-quality data, were excluded from downstream  
907 analyses.

908  
909 We detected a total of 1337786 cells with at least 200 genes quantified. We next applied  
910 stringent filtering on cell quality to remove cells with more than 10% mitochondrial reads and  
911 cells with less than 1000 UMIs quantified. In addition, we only kept cells with a genotype /  
912 patient id assignment using souporecell, and that did not cluster in doublet enriched leiden  
913 clusters during the manual annotation process. This resulted in a dataset of 588389 high-  
914 quality cells from 63 patients and 198 samples that were used for the reported analyses.

915

### 916 **Single-cell Quality Control - Myeloid and non-immune haematopoietic cell**

#### 917 **compartment:**

918 Annotation of myeloid and progenitor compartment was performed using *scanpy*<sup>41</sup> (v1.8.2).  
919 The dataset was initially normalized, and log transformed, and then filtered for highly variable  
920 genes (*scanpy.pp.highly\_variable\_genes*; *min\_mean=0.0125*, *max\_mean=3*, *min\_disp=0.5*)  
921 and scaled (*scanpy.pp.scale*, *max\_value=10*). Dimensionality reduction was performed using  
922 principal component analysis (PCA; *scanpy.tl.pca*), and integration was done using *harmony*  
923<sup>42</sup> (*harmonypy*, v0.0.6). Clustering was performed using the Leiden<sup>43</sup> algorithm (*leidenalg*,  
924 v0.8.9). The marker genes for each cluster were examined using the function  
925 '*scanpy.tl.rank\_genes\_groups*' and each cluster was manually annotated.

926

#### 927 **Single-cell Quality Control - T and NK cell compartment:**

928 The T and NK cell compartment quality control and annotation was performed using the *Seurat*  
929 (v4.1.1) workflow<sup>37</sup>. The expression data was normalized, and log transformed (normalized  
930 to 10,000 counts per cell), 2000 highly variable genes were selected (*FindVariableFeatures*  
931 function, *selection.method = 'vst'*), from which TCR and V(D)J genes were excluded. Prior to  
932 scaling the gene expression data, unwanted sources of variation in the form of total read count  
933 and percentage of mitochondrial genes were regressed out (using *ScaleData* function,  
934 *vars.to.regress* argument). Integration of sequencing samples ('*orig.ident*') using *harmony*<sup>42</sup>  
935 (v1.0) was carried out on the first 30 principal components of the expression data. K-nearest  
936 neighbors (KNN) and shared nearest neighbors (SNN) graphs were calculated from the  
937 harmony adjusted PCs (*FindNeighbours* function). Finally, cells were clustered using the  
938 Leiden algorithm (*FindClusters* function, *method='igraph'*, *algorithm=4*, requiring '*leidenalg*'  
939 python package) and visualized via non-linear dimension reduction UMAP. Clusters were  
940 manually annotated using canonical marker genes through an iterative process of re-  
941 clustering, annotation, identification of potential doublets (presence of distinct cell type marker  
942 genes) and re-clustering. CITE-seq marker proteins CD45RA and CD45RO were used in the  
943 annotation of T EMRA and other memory T cells respectively. All other markers used for  
944 annotations were based on mRNA expression data.

945

#### 946 **Single-cell Quality Control - B cell compartment:**

947 The B cell compartment was integrated using *scVI* (v.0.19.0)<sup>44</sup> with sequencing samples  
948 ('*orig.ident*') as the batch key and raw count data as input. Samples from two individuals were  
949 observed to not integrate well and they were subsequently identified to be samples from  
950 patients with benign chronic lymphocytic leukaemia and were removed from all downstream  
951 analyses (**Table S1**). Percentage mitochondrial content and total counts were provided as  
952 continuous variables to the *scVI* model. Feature selection prior to setting up the *scVI* model



953 was performed as per standard procedures in *scanpy.pp.highly\_variable\_genes* with  
954 *min\_mean=0.0125*, *max\_mean=3*, *min\_disp=0.5*, using the log transformed normalized  
955 expression data (normalized to 10,000 counts per cell). BCR V(D)J genes were also removed  
956 from the highly variable features. Expression of canonical B cell and ASC marker genes and  
957 non-B cell markers were then assessed to manually determine potential multiplets, over  
958 iterative rounds of sub-clustering. The annotations were also assessed against a publicly  
959 available bulk RNAseq gene set of major PBMC cell types<sup>45</sup>. In addition, the single-cell scores  
960 computed after enrichment of the bulk RNA-seq signatures were fitted into a two-component  
961 Gaussian mixture model (*max\_iter=1000*, *covariance\_type='full'*) which distinguished ASCs  
962 from non-ASC B cell clusters. Subsequent sub-clustering and annotations were performed on  
963 the ASCs and non-ASCs separately. To annotate the non-ASC cell clusters, mRNA and  
964 surface molecule expression for select targets (CITE-seq; CD11C and CD27), along with the  
965 Monaco et al.<sup>45</sup> peripheral blood B cell signatures. Isotype usage was checked using the  
966 single-cell and BCR-seq information and used to manually update the cell type annotations,  
967 ensuring that naive B cells, non-switched memory B cells and IgM ASCs are only associated  
968 with IgM and/or IgD while switched memory B cells and IgA/IgG ASCs are only associated  
969 with IgG/IgA isotypes. Other antibody isotype expressing ASCs (IgD/IgE) are labelled as  
970 'B\_ASC\_others'.

## 971 **Integration of Olink Plasma Proteomics**

972  
973 A subset of Wave 1/2020 Cohort (45 individuals, 85 samples) had plasma proteomics  
974 measures from 5 Olink Proteomics Target 96 panels: 'cardiometabolic', 'cardiovascular 2',  
975 'cardiovascular 3', 'inflammation' and 'immune response'. The Olink proteomics data for these  
976 samples has previously been described<sup>14</sup>.

977

## 978 **Longitudinal analysis**

979

980 We defined time from infection as the time from first symptoms, or time from first positive nasal  
981 swab if the latter preceded symptoms (since some cases of COVID-19 were identified by  
982 screening procedures in place for patients attending haemodialysis).

983

984 For longitudinal analysis of enrichment of MSigDB (v7.5) Hallmark, KEGG and Reactome  
985 genesets<sup>46</sup>, the single-cell data was separated to each cell type and the raw count data was  
986 aggregated by sample using '*scuttle::aggregateAcrossCells*' (v1.9.0). Only samples with  
987 more than 10 cells were used for downstream analysis. The pseudo-bulked data was then log  
988 transformed and normalized using '*scuttle::logNormCounts*' and converted to a module score  
989 using '*Seurat::AddModuleScore*'. The module scores were then tested for differential  
990 enrichment over time according to severity strata, using a general linear mixed-effect model  
991 with '*lme4:lmer*' using the following formula:

992 
$$\text{geneset} \sim \text{sex} + \text{age\_scaled} + (1|\text{individual\_id}) + \text{centre} +$$
  
993 
$$PC1_{\text{nonafricanVsAfrican}} + PC2_{\text{asianVsEuropean}} +$$
  
994 
$$\text{splines}::\text{bs}(\text{time\_from\_infection}, \text{degree} = 2) * \text{grouped\_severity}$$

995

996 "Grouped severity" represents overall clinical course, defined by peak illness severity,  
997 binarised into either severe/critical or mild/moderate. The estimated marginal means for the  
998 first 21 days from infection for the relevant genesets were computed using  
999 '*emmeans::emmeans*' with '*time\_from\_infection*' by '*grouped\_severity*'.

1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047

All P values were adjusted using the Benjamini-Hochberg procedure <sup>47</sup>.

### Cell type composition analysis - linear mixed effect model

The cell type abundances per sample were modelled using a generalised linear mixed model using a poisson outcome as described in Yoshida et al <sup>11</sup>. We fitted  $\log_2$  transformed age, and random effect terms on biological sex and inferred ethnicity, to account for collinearity with features of interest. We also fitted a random effect term on the donor identifier to account for donor-to-donor variation but captured the paired effects between longitudinal samples from the same donor. To perform longitudinal analyses, we modelled weeks since onset of disease (onset of symptoms or positive test, whichever came first) as categorical features, and scaled the conditional distribution of fold change estimates to the pre-infection samples that were available, and the pre-infection standard deviation was multiplied by the standard deviation of each other timepoint factor level to account for the increased variance that is introduced by scaling.

### Genetic principal component analysis

To overcome missing self-reported ethnicity data for some donors, we used PCA on genotyping data to quantify and infer genetic ancestry. We took the *souporcell* cluster genotypes of all donors and converted them into a numerical matrix to perform PCA on using *FactoMineR V2.4* <sup>48</sup>. We then mapped self-reported ethnicity onto the genetic PCA results. This revealed that principal component 1 separated individuals with self-reported ethnicities indicating African ancestry from individuals with other ethnicities, while principal component 2 separated individuals of self-reported Asian ancestry from those with self-reported European ancestry. To adjust for the potential confounding effects of ethnicity (since ethnicity is associated with higher risk of severe and fatal COVID-19), we included these 2 principal components (continuous variables) as covariates in all linear mixed models (**Table 1, Supp. Fig. 6**).

### Differential abundance testing - steroid treatment

To examine the effect of steroid treatment on the cell abundance, MiloR package (v.0.99.0) <sup>23</sup> was used. The monocyte population was sub-setted to include only the samples from COVID-19 positive patients who received the steroid treatment during 'Wave 2' of COVID-19. A KNN graph was constructed using the function *'buildGraph'* ( $k=30, d=30$ ) and the cells were assigned to the neighbourhoods on the KNN graph using the function *'makeNhoods'* ( $prop=0.1, k=30, d=30$ ). The number of cells belonging to each sample in each neighbourhood was counted using the function *'countCells'*. We included *'time\_from\_infection'* in the design to account for the length of disease. SpatialFDR < 0.1 was used as a cut off point for significant enrichment/depletion.

### BCR and TCR data processing

Single-cell BCR and TCR data were initially processed with cellranger-*vdj* (v.6.0.0). Single cell TCR data was then converted into a cell by TCR format using *scirpy* v1.10.1 <sup>49</sup>. BCR contigs contained in *all\_contigs.fasta* and *all\_contig\_annotations.csv* were then processed further

1048 using *dandelion*<sup>50</sup> singularity container (v.0.2.4) (<https://www.github.com/zktuong/dandelion>).  
1049 BCRs were then matched to cell barcodes with *dandelion*.

1050

### 1051 **TCR analysis**

1052 After quality control, we recovered 197,330 T cells with fully resolved T cell receptors from 61  
1053 donors and across 187 samples. We identified 127,670 unique TCR clones, defined by a  
1054 unique combination of CDR3a, TRAV, TRAJ, CDR3B, TRBV, TRBJ and donor, at the amino  
1055 acid level. Of these, 93,960 came from COVID-19 positive ESKD patients and thus could be  
1056 analysed longitudinally over the course of infection. A total of 3,727 clones (4%) were captured  
1057 at two or more time points during infection. We further excluded all clones present in pre-  
1058 pandemic samples for analysis related to COVID-19, as these could not have expanded in  
1059 response to SARS-CoV-2, and finally obtained 3,137 clones (3.3%) for longitudinal analysis.  
1060 Clonal frequency within a sample was calculated as total number of clone copies per sample  
1061 over the total number of T cells within the sample. To determine expansion, only clones that  
1062 were sampled at two time points or more within the 0 to 30 days after a positive PCR nasal  
1063 swab, and that were absent in the pre-COVID-19 samples, were used. An expansion was  
1064 noted if the highest clone frequency measured before a specific day since positive swab  
1065 (cutoff) was lower than the lowest frequency measured after that day. If the clone was not  
1066 sampled either before or after the cutoff, the respective frequency was set to 0. The cutoff at  
1067 day 10 was selected as being in agreement with timing of an adaptive immune response. For  
1068 the more stringent definition of expansion as determined by a dual cutoff, the clone frequency  
1069 had to show an increase at the first cutoff and a further increase at the second cutoff. This  
1070 allowed the capture of a steeper increase of clonal frequency over time, at the cost of  
1071 considering fewer total clones.

1072

1073 SARS-CoV-2 specific TCR-epitope pairs were queried from VDJDB. Samples from before the  
1074 pandemic were used to establish a baseline of matches with the database. While a single-  
1075 chain match with the database only indicates a putatively binding TCR, quantifying significant  
1076 differences in these numbers across T cell populations gives insight into antigen-specificity.  
1077 Matches with the database were quantified for expanding and non-expanding clones using  
1078 bar charts, where the error bars show variation across individual COVID-19 patients, and  
1079 significance was determined with a two-sided Mann-Whitney test. To determine which clones  
1080 were expanding the most, expansion was determined as the mean clonal frequency after the  
1081 cutoff day divided by the mean clonal frequency before and sorted in descending order.

1082

1083 Activated T cells were identified by applying the automatic cell type classifier Celltypist (1.2.0,  
1084 model = COVID19\_HumanChallenge\_Blood) and sub-setting to activated T cells.

1085

1086 Cell2TCR (0.1) was used on the clones that showed expansion according to the above  
1087 definition using days 2 and 10 as dual cutoffs, and to generate TCR motifs, while excluding  
1088 TCR sequences of MAI T cells.

1089

1090 TCR analyses were carried out in Python (3.10.2) using pandas (1.4.2), numpy (1.21.6) and  
1091 scanpy (1.9.1), and visualised with matplotlib (3.5.2) and seaborn (0.11.2), in particular  
1092 seaborn's lineplot to show clonal frequency evolution. Statistical tests were carried out using  
1093 the scipy.stats module (1.8.1) and plotted with statannotations (0.5.0). The regression line and  
1094 R2 value were determined with the seaborn's regplot function.

1095

1096 **References**

- 1097 1. Williamson, E. J. *et al.* Factors associated with COVID-19-related death using  
1098 OpenSAFELY. *Nature* **584**, 430–436 (2020).
- 1099 2. Schurink, B. *et al.* Viral presence and immunopathology in patients with lethal COVID-  
1100 19: a prospective autopsy cohort study. *Lancet Microbe* **1**, e290–e299 (2020).
- 1101 3. RECOVERY Collaborative Group *et al.* Dexamethasone in Hospitalized Patients with  
1102 Covid-19. *N. Engl. J. Med.* **384**, 693–704 (2021).
- 1103 4. REMAP-CAP Investigators *et al.* Interleukin-6 Receptor Antagonists in Critically Ill  
1104 Patients with Covid-19. *N. Engl. J. Med.* **384**, 1491–1502 (2021).
- 1105 5. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with  
1106 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*  
1107 **397**, 1637–1645 (2021).
- 1108 6. Huang, J., Zhou, C., Deng, J. & Zhou, J. JAK inhibition as a new treatment strategy for  
1109 patients with COVID-19. *Biochem. Pharmacol.* **202**, 115162 (2022).
- 1110 7. Zoccali, C. *et al.* The systemic nature of CKD. *Nat. Rev. Nephrol.* **13**, 344–358 (2017).
- 1111 8. Sarnak, M. J. & Jaber, B. L. Mortality caused by sepsis in patients with end-stage renal  
1112 disease compared with the general population. *Kidney Int.* **58**, 1758–1764 (2000).
- 1113 9. Domínguez Conde, C. *et al.* Cross-tissue immune cell analysis reveals tissue-specific  
1114 features in humans. *Science* **376**, eabl5197 (2022).
- 1115 10. Stephenson, E. *et al.* Single-cell multi-omics analysis of the immune response in  
1116 COVID-19. *Nat. Med.* **27**, 904–916 (2021).
- 1117 11. Yoshida, M. *et al.* Local and systemic responses to SARS-CoV-2 infection in children  
1118 and adults. *Nature* **602**, 321–327 (2022).
- 1119 12. Chan, K. R. *et al.* Early peripheral blood MCEMP1 and HLA-DRA expression predicts  
1120 COVID-19 prognosis. *EBioMedicine* **89**, 104472 (2023).
- 1121 13. Mann, E. R. *et al.* Longitudinal immune profiling reveals key myeloid signatures  
1122 associated with COVID-19. *Sci Immunol* **5**, (2020).
- 1123 14. Gisby, J. *et al.* Longitudinal proteomic profiling of dialysis patients with COVID-19




- 1124 reveals markers of severity and predictors of death. *Elife* **10**, (2021).
- 1125 15. Filbin, M. R. *et al.* Longitudinal proteomic analysis of severe COVID-19 reveals survival-  
1126 associated signatures, tissue-specific cell death, and cell-cell interactions. *Cell Rep Med*  
1127 **2**, 100287 (2021).
- 1128 16. Ugalde, A. P. *et al.* Autophagy-linked plasma and lysosomal membrane protein PLAC8  
1129 is a key host factor for SARS-CoV-2 entry into human cells. *EMBO J.* **41**, e110727  
1130 (2022).
- 1131 17. Thwaites, R. S. *et al.* Inflammatory profiles across the spectrum of disease reveal a  
1132 distinct role for GM-CSF in severe COVID-19. *Sci Immunol* **6**, (2021).
- 1133 18. Goncharov, M. *et al.* VDJdb in the pandemic era: a compendium of T cell receptors  
1134 specific for SARS-CoV-2. *Nat. Methods* **19**, 1017–1019 (2022).
- 1135 19. Lindeboom, R. G. H. *et al.* Human SARS-CoV-2 challenge resolves local and systemic  
1136 response dynamics. *bioRxiv* (2023) doi:10.1101/2023.04.13.23288227.
- 1137 20. Coutinho, A. E. & Chapman, K. E. The anti-inflammatory and immunosuppressive  
1138 effects of glucocorticoids, recent developments and mechanistic insights. *Mol. Cell.*  
1139 *Endocrinol.* **335**, 2–13 (2011).
- 1140 21. Ehrchen, J. M., Roth, J. & Barczyk-Kahlert, K. More Than Suppression: Glucocorticoid  
1141 Action on Monocytes and Macrophages. *Front. Immunol.* **10**, 2028 (2019).
- 1142 22. Ehrchen, J. *et al.* Glucocorticoids induce differentiation of a specifically activated, anti-  
1143 inflammatory subtype of human monocytes. *Blood* **109**, 1265–1274 (2007).
- 1144 23. Dann, E., Henderson, N. C., Teichmann, S. A., Morgan, M. D. & Marioni, J. C.  
1145 Differential abundance testing on single-cell data using k-nearest neighbor graphs. *Nat.*  
1146 *Biotechnol.* **40**, 245–253 (2022).
- 1147 24. Skytthe, M. K., Graversen, J. H. & Moestrup, S. K. Targeting of CD163 Macrophages in  
1148 Inflammatory and Malignant Diseases. *Int. J. Mol. Sci.* **21**, (2020).
- 1149 25. Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation.  
1150 *Nat. Rev. Immunol.* **8**, 958–969 (2008).
- 1151 26. Qu, R. *et al.* Glucocorticoids improve the balance of M1/M2 macrophage polarization in


- 1152 experimental autoimmune uveitis through the P38MAPK-MEF2C axis. *Int.*  
1153 *Immunopharmacol.* **120**, 110392 (2023).
- 1154 27. Xue, J. *et al.* Transcriptome-based network analysis reveals a spectrum model of  
1155 human macrophage activation. *Immunity* **40**, 274–288 (2014).
- 1156 28. Ogawa, Y. *et al.* Peripherally administered orexin improves survival of mice with  
1157 endotoxin shock. *Elife* **5**, (2016).
- 1158 29. Becquet, L. *et al.* Systemic administration of orexin A ameliorates established  
1159 experimental autoimmune encephalomyelitis by diminishing neuroinflammation. *J.*  
1160 *Neuroinflammation* **16**, 64 (2019).
- 1161 30. Tse, L. V. *et al.* Genomewide CRISPR knockout screen identified PLAC8 as an  
1162 essential factor for SARS-CoVs infection. *Proc. Natl. Acad. Sci. U. S. A.* **119**,  
1163 e2118126119 (2022).
- 1164 31. Ren, X. *et al.* COVID-19 immune features revealed by a large-scale single-cell  
1165 transcriptome atlas. *Cell* **184**, 1895–1913.e19 (2021).
- 1166 32. Zhao, J. H. *et al.* Genetics of circulating inflammatory proteins identifies drivers of  
1167 immune-mediated disease risk and therapeutic targets. *Nat. Immunol.* **24**, 1540–1551  
1168 (2023).
- 1169 33. Kokkotis, G. *et al.* Systematic review with meta-analysis: COVID-19 outcomes in  
1170 patients receiving anti-TNF treatments. *Aliment. Pharmacol. Ther.* **55**, 154–167 (2022).
- 1171 34. Khan, S. F. & Bowman, B. T. Vaccinating the Patient with ESKD. *Clin. J. Am. Soc.*  
1172 *Nephrol.* **14**, 1525–1527 (2019).
- 1173 35. Carr, E. J. *et al.* Neutralising antibodies after COVID-19 vaccination in UK  
1174 haemodialysis patients. *The Lancet* vol. 398 1038–1041 (2021).
- 1175 36. Carr, E. J. *et al.* Omicron neutralising antibodies after COVID-19 vaccination in  
1176 haemodialysis patients. *The Lancet* vol. 399 800–802 (2022).
- 1177 37. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell  
1178 transcriptomic data across different conditions, technologies, and species. *Nat.*  
1179 *Biotechnol.* **36**, 411–420 (2018).

- 1180 38. Young, M. D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-  
1181 based single-cell RNA sequencing data. *Gigascience* **9**, (2020).
- 1182 39. Heaton, H. *et al.* Souporcell: robust clustering of single-cell RNA-seq data by genotype  
1183 without reference genotypes. *Nat. Methods* **17**, 615–620 (2020).
- 1184 40. McCarthy, D. J. *et al.* Cardelino: computational integration of somatic clonal  
1185 substructure and single-cell transcriptomes. *Nat. Methods* **17**, 414–421 (2020).
- 1186 41. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression  
1187 data analysis. *Genome Biol.* **19**, 15 (2018).
- 1188 42. Korsunsky, I. *et al.* Fast, sensitive and accurate integration of single-cell data with  
1189 Harmony. *Nat. Methods* **16**, 1289–1296 (2019).
- 1190 43. Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well-  
1191 connected communities. *Sci. Rep.* **9**, 5233 (2019).
- 1192 44. Lopez, R., Regier, J., Cole, M. B., Jordan, M. I. & Yosef, N. Deep generative modeling  
1193 for single-cell transcriptomics. *Nat. Methods* **15**, 1053–1058 (2018).
- 1194 45. Monaco, G. *et al.* RNA-Seq Signatures Normalized by mRNA Abundance Allow  
1195 Absolute Deconvolution of Human Immune Cell Types. *Cell Rep.* **26**, 1627–1640.e7  
1196 (2019).
- 1197 46. Liberzon, A. *et al.* The Molecular Signatures Database (MSigDB) hallmark gene set  
1198 collection. *Cell Syst* **1**, 417–425 (2015).
- 1199 47. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and  
1200 powerful approach to multiple testing. *J. R. Stat. Soc.* **57**, 289–300 (1995).
- 1201 48. Lê, S., Josse, J. & Husson, F. FactoMineR: An R Package for Multivariate Analysis. *J.*  
1202 *Stat. Softw.* **25**, 1–18 (2008).
- 1203 49. Sturm, G. *et al.* Scirpy: a Scanpy extension for analyzing single-cell T-cell receptor-  
1204 sequencing data. *Bioinformatics* **36**, 4817–4818 (2020).
- 1205 50. Suo, C. *et al.* Dandelion uses the single-cell adaptive immune receptor repertoire to  
1206 explore lymphocyte developmental origins. *Nat. Biotechnol.* **42**, 40–51 (2024).


**a**






**b**




**c**









**a**




**b**




**c**











**d**




**e**














**a**




**b**




**c**




**d**




**a**



**b**



**c**



**d**

